SCHEMBL6446629

SCHEMBL6446629

N#Cc1c(NCc2ccc(C(F)(F)F)cc2)nc(N)nc1C1=CCCO1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.47
HRH4 Q9H3N8 1/20 0.40
EPHX2 P34913 1/20 0.36
EGFR P00533 1/20 0.36
VNN1 O95497 1/20 0.35
CHUK O15111 1/20 0.34
TPH1 P17752 2/20 0.34
KDM4E B2RXH2 3/20 0.34
RPS6KB1 P23443 2/20 0.34
MEN1 O00255 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 2/20 0.34
KMT2A Q03164 2/20 0.34
GAA P10253 1/20 0.34
HTT P42858 1/20 0.34
AURKA O14965 1/20 0.34
AURKB Q96GD4 1/20 0.34
NPSR1 Q6W5P4 1/20 0.33
GHSR Q92847 1/20 0.33
TLR8 Q9NR97 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441227 0.82 HIF1A (0.39) APPHRH4EGFRCHUKTPH1
SCHEMBL5040159 0.79 ADORA2A (0.50) APPKDM4EMEN1ALDH1A1HPGD
SCHEMBL6440590 0.77 ADORA1 (0.39) KDM4EMEN1ALDH1A1KMT2ANPSR1
SCHEMBL6444939 0.77 APP (0.53) APPHRH4EPHX2EGFRCHUK
SCHEMBL5041823 0.74 TLR7 (0.35) APPKDM4EMEN1ALDH1A1HPGD
SCHEMBL6449459 0.70 APP (0.52) APPHRH4EPHX2EGFRCHUK
SCHEMBL5039776 0.69 APP (0.53) APPEGFRKDM4ERPS6KB1ALDH1A1
SCHEMBL6443545 0.67 ADORA1 (0.63) APPCHUK
SCHEMBL6444821 0.67 ADORA2A (0.51) APPKDM4EMEN1ALDH1A1HPGD
SCHEMBL6444623 0.67 CYP1A2 (0.50) KDM4EMEN1ALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
CN-1438890-A Adenosine receptor modulators HOFFMANNLA ROCHE AG F (CH) 2003-08-27 CN disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 APP 477/4885HRH4 140/4885EPHX2 2497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.